Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
ACTIVE NOT RECRUITING
NCT06873724
PHASE1
A Study of SPY003-207 in Healthy Volunteers
Sponsor: Spyre Therapeutics, Inc.
View on ClinicalTrials.gov
Summary
This is a Phase 1, randomized, double-blind, placebo-controlled, single dose, first in human safety, tolerability, and pharmacokinetic study of SPY003-207 in healthy participants.
Official title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of SPY003-207 in Healthy Participants
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
59
Start Date
2025-03-10
Completion Date
2026-11-18
Last Updated
2026-03-20
Healthy Volunteers
Yes
Conditions
Interventions
DRUG
SPY003-207
Experimental
OTHER
Placebo
Placebo
Locations (2)
Spyre Site 2
Cypress, California, United States
Spyre Site 1
Montreal, Quebec, Canada